Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
Antivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels. Currently, two anti-VEGF drugs are registered for ophthalmological use, and the search for new molecu...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2019-06-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850047658919460864 |
|---|---|
| author | R. R. Fayzrakhmanov |
| author_facet | R. R. Fayzrakhmanov |
| author_sort | R. R. Fayzrakhmanov |
| collection | DOAJ |
| description | Antivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels. Currently, two anti-VEGF drugs are registered for ophthalmological use, and the search for new molecules is only gaining momentum. Studying new approaches to treatment and developing innovative drugs, modern medicine relies on the data from international randomized clinical trials (RCT). The fact that this direction attracts much scientific interest is explained by high reliability of the data obtained with RCTs. However, when analyzing the effectiveness of anti-VEGF therapy in patients with nAMD in routine clinical practice, many ophthalmologists are confronted with discrepancies between the expected morphological and functional results as predicted by RCTs and those obtained in reality. It is thus important to bear in mind that RCTs simply determine how the dynamics of morphofunctional parameters should look like, whilst the ideal result is only achievable through correct implementation of therapeutic strategy in real clinical practice. The results obtained in the practice of any specialist wholly depend on how carefully the prescribed treatment protocols are followed by doctors and patients, how burdensome the treatment is, as well as on the potential of the medication. This literary review offers a comparative analysis of the results achieved by using anti-VEGF drugs (ranibizumab and aflibercept) obtained in key RCTs and in routine clinical treatment of nAMD patients. |
| format | Article |
| id | doaj-art-9368e32c50934e6cbfcad9d8b4aced03 |
| institution | DOAJ |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| publishDate | 2019-06-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj-art-9368e32c50934e6cbfcad9d8b4aced032025-08-20T02:54:10ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602019-06-011229710510.21516/2072-0076-2019-12-2-97-105227Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practiceR. R. Fayzrakhmanov0N.I. Pirogov National Medical and Surgical CenterAntivasoproliferative therapy is a revolutionary trend in the treatment of neovascular age-related macular degeneration (nAMD), as it is aimed at blocking growth factors of the newly formed vessels. Currently, two anti-VEGF drugs are registered for ophthalmological use, and the search for new molecules is only gaining momentum. Studying new approaches to treatment and developing innovative drugs, modern medicine relies on the data from international randomized clinical trials (RCT). The fact that this direction attracts much scientific interest is explained by high reliability of the data obtained with RCTs. However, when analyzing the effectiveness of anti-VEGF therapy in patients with nAMD in routine clinical practice, many ophthalmologists are confronted with discrepancies between the expected morphological and functional results as predicted by RCTs and those obtained in reality. It is thus important to bear in mind that RCTs simply determine how the dynamics of morphofunctional parameters should look like, whilst the ideal result is only achievable through correct implementation of therapeutic strategy in real clinical practice. The results obtained in the practice of any specialist wholly depend on how carefully the prescribed treatment protocols are followed by doctors and patients, how burdensome the treatment is, as well as on the potential of the medication. This literary review offers a comparative analysis of the results achieved by using anti-VEGF drugs (ranibizumab and aflibercept) obtained in key RCTs and in routine clinical treatment of nAMD patients.https://roj.igb.ru/jour/article/view/279neovascular age-related macular degenerationnamdafliberceptranibizumabroutine clinical practice |
| spellingShingle | R. R. Fayzrakhmanov Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice Российский офтальмологический журнал neovascular age-related macular degeneration namd aflibercept ranibizumab routine clinical practice |
| title | Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice |
| title_full | Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice |
| title_fullStr | Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice |
| title_full_unstemmed | Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice |
| title_short | Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice |
| title_sort | anti vegf therapy of neovascular age related macular degeneration from randomized trials to routine clinical practice |
| topic | neovascular age-related macular degeneration namd aflibercept ranibizumab routine clinical practice |
| url | https://roj.igb.ru/jour/article/view/279 |
| work_keys_str_mv | AT rrfayzrakhmanov antivegftherapyofneovascularagerelatedmaculardegenerationfromrandomizedtrialstoroutineclinicalpractice |